Pharmacological Management Of Newly Detected Atrial Fibrillation

Publication Date: April 1, 2017

Key Points

Key Points

  • Atrial fibrillation (AF) is one of the most common types of arrhythmia in adults worldwide, with an estimated 2.7–6.1 million people affected in the United States.
  • Because AF is more common in adults >65 years of age, this figure will continue to rise as the population ages.
  • AF presents as a change in heart rate with an irregular pattern, with symptoms that may worsen/change over time.
  • AF can occur as episodes (paroxysmal) or continuously (persistent).
    • Symptom presentation can vary among patients, with some being asymptomatic and others complaining of irregular heart rate, heart palpitations, lightheadedness, extreme fatigue, shortness of breath, anxiety, and chest pain.
  • In addition to an increase in mortality, myocardial infarction, heart failure exacerbation and cardiomyopathy, patients who have AF have a significantly increased risk of stroke.
    • Almost a quarter of all strokes in the elderly are related to AF.
  • Management options for AF involve rate control, rhythm control, and prevention of thromboembolic events.
    • Options include medications to slow the heart rate, medications to achieve and maintain a regular rhythm, electrical cardioversion, ablation, and other surgical interventions.
  • Stroke prophylaxis is a mainstay of management for individuals with AF who have additional risk factors for stroke.
  • Stroke risk can be predicted using the continuous CHADS2 or continuous CHA2DS2-VASc risk assessment scores (See Tables 1–3).
  • Bleeding risk can also be assessed for patients treated with anticoagulants or aspirin. The HAS-BLED scale (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly) is the most studied and most commonly used.
  • Many of the risk factors for bleeding are the same as those for stroke, making it challenging to estimate the trade-off between stroke risk and
    risk of bleeding.

Treatment

...Treatment...

...ate control is preferred over rhythm...


...options for rate-control therapy includ...


Lenient rate control (


...ians should discuss the risk of stroke a...

...ns should consider using the continuous...

...-BLED for prediction of risk for bl...


...linicians should discuss the risk of stroke and...


...ans should consider using the continuous CHADS2...


and HAS-BLED for prediction of ris...


...have atrial fibrillation should receive...


...nt with anticoagulant and antiplatelet t...


Table 1. CHADS2 Risk Assessment ScoreHaving t...


...able 2. CHA2DS2-VASc Risk Assessment S...


...atment Based on CHADS2 ScoreHaving trouble view...


...al Anticoagulants for Stroke Prevention in Patie...


...Increased Risk of Major Bleeding with Dual T...